8-K: Greenwich LifeSciences Changes Auditors Amid Persistent Internal Control Weaknesses

Greenwich LifeSciences, Inc. has dismissed RBSM LLP and engaged MaloneBailey LLP as its new independent registered public accounting firm, following disclosures of material weaknesses in internal controls over financial reporting.

Summary

• Greenwich LifeSciences, Inc. (GLSI) dismissed RBSM LLP as its independent registered public accounting firm on July 19, 2025.
• MaloneBailey LLP was engaged as the new independent registered public accounting firm to audit the company's consolidated financial statements for the year ended December 31, 2025.
• RBSM's reports for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion, disclaimer, or qualification regarding uncertainty, audit scope, or accounting principles.
• The company has reported material weaknesses in its internal control over financial reporting for the fiscal years ended December 31, 2024 and 2023, as well as for the quarters ended March 31, 2024, June 30, 2024, September 30, 2024, and March 31, 2025.
• No disagreements on accounting principles, financial statement disclosure, or auditing scope/procedure occurred between the company and RBSM.
• The company did not consult with MaloneBailey regarding specific accounting or auditing issues prior to their engagement.

Sentiment

Score: 3

Explanation: The change in auditor, while not explicitly negative due to disagreements, is coupled with the significant and persistent disclosure of material weaknesses in internal controls. This raises concerns about the reliability of financial reporting and operational efficiency, leading to a negative sentiment.

Positives

• RBSM LLP's audit reports for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion, a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.
• There were no disagreements between the company and RBSM LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

Negatives

• The company has consistently reported material weaknesses in its internal control over financial reporting for the fiscal years ended December 31, 2024 and 2023.
• Material weaknesses in internal control over financial reporting were also reported for the quarters ended March 31, 2024, June 30, 2024, September 30, 2024, and March 31, 2025.

Risks

• Material Weaknesses in Internal Control Over Financial Reporting: The company has identified and reported material weaknesses in its internal controls for multiple past periods (fiscal years 2023, 2024, and Q1, Q2, Q3 2024, Q1 2025), which could lead to financial misstatements, fraud, or an inability to accurately report financial results.
• Auditor Transition Risk: The transition to a new auditor (MaloneBailey LLP) may involve a period of adjustment and potential for delays or increased scrutiny, although the company states no prior disagreements or consultations.
• Regulatory Scrutiny: Persistent material weaknesses could attract increased scrutiny from the SEC or other regulatory bodies.
• Investor Confidence: The disclosure of ongoing material weaknesses may negatively impact investor confidence in the company's financial reporting reliability.

Future Outlook

No forward-looking statements or guidance provided in this filing.

Management Comments

• The Audit Committee has discussed the material weaknesses in the company's internal control over financial reporting with RBSM and has authorized RBSM to respond fully to the inquiries of MaloneBailey, the company's new independent registered public accountants, concerning such weakness.

Industry Context

This filing primarily concerns corporate governance and financial reporting compliance rather than specific industry trends. However, robust internal controls are crucial across all industries, particularly in highly regulated sectors like life sciences, where accurate financial reporting is paramount for investor confidence and regulatory compliance.

Comparison to Industry Standards

• The presence of persistent material weaknesses in internal controls is generally below industry best practices for public companies, which strive for effective internal controls to ensure reliable financial reporting.
• Leading companies in the life sciences sector, such as Pfizer or Johnson & Johnson, maintain extensive internal control frameworks to prevent such issues and ensure the integrity of their financial disclosures.

Corporate Governance

Stakeholder Impact

• Shareholders: May face increased uncertainty regarding the accuracy and reliability of financial statements due to persistent material weaknesses in internal controls. The auditor change could be viewed as a step towards addressing these issues, but the underlying problem remains.
• Regulatory Authorities: The SEC will likely continue to monitor the company's progress in remediating the disclosed material weaknesses.

Next Steps

• MaloneBailey LLP will audit the company's consolidated financial statements for the year ended December 31, 2025.
• The company will need to address and remediate the identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

While the auditor change itself is a standard corporate action, the persistent material weaknesses in internal controls are a significant concern. This indicates potential issues with financial reporting reliability. Until there is clear evidence of remediation of these material weaknesses, a 'hold' recommendation is appropriate, suggesting investors monitor the situation closely without taking new positions. The lack of disagreements with the previous auditor is a minor positive, but it doesn't outweigh the control deficiencies.

Keywords

Greenwich LifeSciences, GLSI, SEC filing, Form 8-K, auditor change, independent registered public accounting firm, RBSM LLP, MaloneBailey LLP, material weaknesses, internal control over financial reporting, corporate governance, biotechnology, pharmaceuticals, life sciences